On 4 February 2026, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer samples into high-resolution, multimodal datasets, backed by £18.9 million in ...

First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology "Scientists can now ...

Genomics is collaborating with PharosAI and leading UK institutions to build a large multimodal cancer dataset using its Xenium spatial platform. The project will use decades of NHS cancer samples to ...

Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ Spatial Transcriptomics services are now ...

Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (TXG) ...

Moby Strategic Performance Drivers and Market Dynamics. Management attributed Q4 performance to a modest year-end budget ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology ...

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), today announced a research collaboration for the Target ...

HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ ...